Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.07.2023 | Case report

Capecitabine/lutetium-(177Lu)-oxodotreotide/temozolomide

Various toxicities and lack of efficacy: 10 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Kennedy KR, et al. Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy. Cancer 128: 2182-2192, No. 11, et al. Jun 2022. Available from: URL: http://doi.org/10.1002/cncr.34191 Kennedy KR, et al. Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy. Cancer 128: 2182-2192, No. 11, et al. Jun 2022. Available from: URL: http://​doi.​org/​10.​1002/​cncr.​34191
Metadaten
Titel
Capecitabine/lutetium-(177Lu)-oxodotreotide/temozolomide
Various toxicities and lack of efficacy: 10 case reports
Publikationsdatum
01.07.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-42202-z

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Eculizumab

Case report

Linezolid

Case report

Multiple drugs

Case report

Quetiapine